COMPANY

Microbion

HQ: Bozeman, MT source · microbioncorp.com ↗ · Mountain

Keywords: diabetic foot ulcer lung infection respiratory Diabetic Foot Infection Bacterial Infection MBN-101

Location: Bozeman, MT · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Jun 13, 2022 Trial start Phase 2: Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients source ↗
Mar 6, 2017 Trial start Phase 1: A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI source ↗
May 24, 2016 Trial start Phase 2: Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05174806	Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients	Phase 2	Completed	Jun 13, 2022	Jan 19, 2024 (actual)
NCT02436876	Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites	Phase 2	Completed	May 24, 2016	Oct 27, 2017 (actual)
NCT02723539	A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI	Phase 1	Completed	Mar 6, 2017	Nov 1, 2017 (actual)

Annual award amounts. Total $100K.

Jun 30, 2003 NIH award 1R43AI050417-01A2 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI BAKER, BRETT HUGH JAMES; recipient as written: MICROBION CORPORATION, BOZEMAN, MT. Disinfectant Efficacy on Surface B source ↗